PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-23. Numbers and descriptions here follow the published literature rather than marketing material.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Development, implementation, analysis and reporting Leading quality improvement initiatives based on audit findings. An example from the UK is the National Comparative Audit of Blood Transfusion (NCABT), which is a programme of clinical audits that look at the use and administration of blood and blood components in the National Health System (NHS) and independent hospitals in the UK. This audit programme's objectives are to provide evidence that blood is being prescribed and used appropriately and administered safely. It also highlights where practice is deviating from the guidelines and how this might affect patient outcomes. Data collection for these audits can be undertaken by a variety of health care professionals within the participating organisations, however the majority of the data collection and data submission is undertaken by the TP.
== Natural occurrence == The acid is found in Centella asiatica (Gotu Kola). Other sources include Centella cordifolia and Hydrocotyle umbellata. The compound is closely related to Asiatic acid and is known for its various pharmacological properties, including anti-inflammatory, wound-healing, anti-oxidant, and neuroprotective effects. It is often studied alongside other bioactive compounds from Centella asiatica.
He considered the West Midlands dialect of Middle English to be his own "native language", and, as he wrote to W. H. Auden in 1955, "I am a West-midlander by blood (and took to early west-midland Middle English as a known tongue as soon as I set eyes on it)."
Max Vasmer's etymological dictionary traces the name to the Tatar Turkic word kazak, kozak, in which cosac meant 'free man' but also 'conqueror'. The ethnonym Kazakh is from the same Turkic root. In written sources, the name is first attested in the Codex Cumanicus from the 13th century. Larysa Pritsak (2024) grouped the earliest references of the word Cossack(s) into three groups:
Sources: en.wikipedia.org
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
Chronic inflammation is inflammation that lasts for months or years. Macrophages, lymphocytes, and plasma cells predominate in chronic inflammation, in contrast to the neutrophils that predominate in acute inflammation. Diabetes, cardiovascular disease, allergies, and chronic obstructive pulmonary disease are examples of diseases mediated by chronic inflammation. Obesity, smoking, stress and insufficient diet are some of the factors that promote chronic inflammation.
Rush toured Permanent Waves for six months through 1980 to more than 650,000 people across 96 shows, becoming their first tour to make a profit. After the tour, Rush joined rock band Max Webster from Toronto and recorded "Battle Scar" for their 1980 album, Universal Juveniles. Max Webster's lyricist, Pye Dubois, offered the band lyrics to a song he had written. The band accepted, and after reworking by Peart the song became "Tom Sawyer".
The pharmacology of cyproterone acetate (CPA) concerns the pharmacology (pharmacodynamics, pharmacokinetics, and routes of administration) of the steroidal antiandrogen and progestin medication cyproterone acetate. CPA blocks the effects of androgens like testosterone in the body, which it does by preventing them from interacting with their biological target, the androgen receptor (AR), and by reducing their production by the gonads and hence their concentrations in the body. In addition, it has progesterone-like effects by activating the progesterone receptor (PR). By activating the PR, CPA has antigonadotropic effects and can inhibit fertility and suppress sex hormone production in both men and women. CPA can also produce weak and partial cortisol-like effects at very high doses under certain circumstances by activating the glucocorticoid receptor (GR). CPA can be taken by mouth or by injection into muscle. It has near-complete oral bioavailability, is highly and exclusively bound to albumin in terms of plasma protein binding, is metabolized in the liver by hydroxylation and conjugation, has 15β-hydroxycyproterone acetate (15β-OH-CPA) as a single major active metabolite, has a long elimination half-life of about 2 to 4 days regardless of route of administration, and is excreted in feces primarily and to a lesser extent in urine.
Three whales die after the pod of about 30 whales re-stranded at Pūponga Beach in Golden Bay despite efforts to refloat them. 20 January – A second pod of about 11 whales is stranded near Taupata Point in the Golden Bay. 21 January – DOC staff and volunteers succeed in refloating the initial pod of 30 whales and ten whales from the second pod. One of the whales from the second pod dies. 22 January: Ten whales are re-stranded in Golden Bay, prompting a response from DOC and volunteers. The Body Shop NZ goes into voluntary administration. Media company NZME announces plans to cut 14 reporting and 24 production jobs as part of a restructuring process. 23 January: DOC staff, Project Jonah and community volunteers succeed in refloating the ten stranded whales in Golden Bay. Prime Minister Luxon gives his State of the Nation address. He announces that the existing Crown Research Institutes will be merged into three new Public Research Organisations and that the Government will establish a new foreign investment agency. 25 January – A tornado and severe storm hits Mangawhai and surrounding areas, causing two serious injuries, damage to about 50 properties and power outages affecting 4,700 homes. 27 January: In order to attract digital nomads, a 'digital nomad' visa is announced to allow non-residents to work in New Zealand for up to nine months, given they work entirely remotely for a non-New Zealand company. The work will be untaxed for up to 90 days.
Sources: en.wikipedia.org
, regardless of secondary structure. The modern versions of these libraries as used in most software are presented as multidimensional distributions of probability or frequency, where the peaks correspond to the dihedral-angle conformations considered as individual rotamers in the lists. Some versions are based on very carefully curated data and are used primarily for structure validation, while others emphasize relative frequencies in much larger data sets and are the form used primarily for structure prediction, such as the Dunbrack rotamer libraries. Side-chain packing methods are most useful for analyzing the protein's hydrophobic core, where side chains are more closely packed; they have more difficulty addressing the looser constraints and higher flexibility of surface residues, which often occupy multiple rotamer conformations rather than just one.
When diagnosed with myasthenia gravis, an individual can be stratified into distinct subgroups based on the clinical features and serological status, e.g., affected muscle group, age of onset, thymic abnormalities, and profile of serum autoantibodies. Based on the affected muscle group, people with myasthenia gravis can be sub-grouped into ocular myasthenia gravis or generalized myasthenia gravis. Ocular myasthenia gravis is characterized by exclusively ocular symptoms, droopy eyelids, or double vision. Generalized myasthenia gravis has muscle weakness with a variable combination of the bulbar, axial, or limb and respiratory muscles. People with myasthenia gravis can also be sub-grouped by the age of onset: juvenile-onset myasthenia gravis (onset age ≤ 18 years of age), early-onset MG (EOMG; 19–50 years of age), late-onset MG (LOMG; onset > 50 years of age), and very late-onset (VLOMG; onset age ≥ 65 years of age). The subgroup of the autoantibody profile includes AChR seropositive, MuSK seropositive, LRP4 seropositive, and agrin seropositive.
==== 900–999 ==== Act of Sederunt (Rules of the Court of Session Amendment No. 2) (Fees of Solicitors) 1993 (S.I. 1993/900) Further Education (Exclusion of Land from Transfer) Order 1993 (S.I. 1993/901) Greater Manchester and Lancashire (County and Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/902) Dyfed-Powys Police (Amalgamation) (Amendment) Order 1993 (S.I. 1993/909) National Rivers Authority (Anglian Region) (Reconstitution of the Witham Third District Internal Drainage Board) Order 1993 (S.I. 1993/910) Plymouth Development Corporation (Area and Constitution) Order 1993 (S.I. 1993/911) Electricity (Restrictive Trade Practices Act 1976) (Exemption) Order 1993 (S.I. 1993/912) Child Support (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/913) Act of Sederunt (Child Support Act 1991) (Amendment of Ordinary Cause and Summary Cause Rules) 1993 (S.I. 1993/919) Act of Sederunt (Child Support Rules) 1993 (S.I. 1993/920) Act of Sederunt (Bankruptcy Rules) 1993 (S.I. 1993/921) Land Registration (Scotland) Act 1979 (Commencement No. 7) Order 1993 (S.I. 1993/922) Dairy Produce Quotas Regulations 1993 (S.I. 1993/923) Education (Dissolution of the Council for National Academic Awards) Order 1993 (S.I. 1993/924) Child Support (Maintenance Assessments and Special Cases) Amendment Regulations 1993 (S.I. 1993/925) Greater Manchester and Lancashire (County and District Boundaries) Order 1993 (S.I. 1993/926) Secure Tenancies (Designated Courses) (Amendment) Regulations 1993 (S.I.
Kallikrein-6 is a protein that in humans is encoded by the KLK6 gene. Kallikrein-6 is also referred to as neurosin, protease M, hK6, or zyme. It is a 223 amino acid sequence, derived from its 244 original form, which contains a 16 residue presignal and 5 residue activation peptide.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.